# A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

> **NCT00189358** · PHASE2 · COMPLETED · sponsor: **AGO Study Group**

## Conditions studied

- Ovarian Cancer
- Cancer of the Fallopian Tube
- Peritoneal Cancer

## Interventions

- **DRUG:** ZD1839
- **DRUG:** tamoxifen

## Key facts

- **NCT ID:** NCT00189358
- **Lead sponsor:** AGO Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2010-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189358, "A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00189358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*